Skip to main content
. 2023 Mar 27;11:1157547. doi: 10.3389/fped.2023.1157547

Figure 1.

Figure 1

Association between proton pump inhibitor (PPI) exposure in different observation periods and the development of an autoimmune disease (AD), represented by type 1 diabetes (DM), autoimmune thyroiditis (AIT), juvenile idiopathic arthritis (JIA), or inflammatory bowel diseases (IBD).